Pihlajalinna Oyj Valuation
Is PIHLIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PIHLIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PIHLIS (€11.05) is trading below our estimate of fair value (€28.68)
Significantly Below Fair Value: PIHLIS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PIHLIS?
Key metric: As PIHLIS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PIHLIS's PE Ratio? | |
|---|---|
| PE Ratio | 19.1x |
| Earnings | €13.03m |
| Market Cap | €248.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 11.5x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does PIHLIS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 57x | ||
REG1V Revenio Group Oyj | 37.6x | 19.0% | €718.1m |
6197 Solasto | 144.2x | 23.5% | JP¥43.6b |
VMD Viemed Healthcare | 33x | 49.4% | CA$311.8m |
7840 France Bed HoldingsLtd | 13.3x | n/a | JP¥42.7b |
PIHLIS Pihlajalinna Oyj | 19.1x | 14.2% | €248.4m |
Price-To-Earnings vs Peers: PIHLIS is good value based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (57x).
Price to Earnings Ratio vs Industry
How does PIHLIS's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: PIHLIS is expensive based on its Price-To-Earnings Ratio (19.1x) compared to the European Healthcare industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is PIHLIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19.1x |
| Fair PE Ratio | 25.9x |
Price-To-Earnings vs Fair Ratio: PIHLIS is good value based on its Price-To-Earnings Ratio (19.1x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.05 | €11.68 +5.7% | 11.8% | €13.30 | €9.50 | n/a | 4 |
| Nov ’25 | €10.70 | €11.08 +3.5% | 8.5% | €11.80 | €9.50 | n/a | 4 |
| Oct ’25 | €9.66 | €10.68 +10.5% | 6.4% | €11.20 | €9.50 | n/a | 4 |
| Sep ’25 | €9.92 | €10.68 +7.6% | 6.4% | €11.20 | €9.50 | n/a | 4 |
| Aug ’25 | €9.88 | €9.80 -0.8% | 5.1% | €10.50 | €9.20 | n/a | 4 |
| Jul ’25 | €9.38 | €9.68 +3.1% | 3.5% | €10.00 | €9.20 | n/a | 4 |
| Jun ’25 | €9.30 | €9.35 +0.5% | 9.2% | €10.00 | €7.90 | n/a | 4 |
| May ’25 | €8.28 | €8.30 +0.2% | 6.0% | €9.00 | €7.90 | n/a | 3 |
| Apr ’25 | €7.61 | €8.30 +9.1% | 6.0% | €9.00 | €7.90 | n/a | 3 |
| Mar ’25 | €8.00 | €8.30 +3.8% | 6.0% | €9.00 | €7.90 | n/a | 3 |
| Feb ’25 | €7.17 | €8.30 +15.8% | 6.0% | €9.00 | €7.90 | n/a | 3 |
| Jan ’25 | €7.06 | €8.57 +21.3% | 5.6% | €9.00 | €7.90 | n/a | 3 |
| Dec ’24 | €7.06 | €8.57 +21.3% | 5.6% | €9.00 | €7.90 | n/a | 3 |
| Nov ’24 | €7.39 | €8.93 +20.9% | 4.7% | €9.50 | €8.50 | €10.70 | 3 |
| Oct ’24 | €8.11 | €8.95 +10.4% | 4.1% | €9.50 | €8.50 | €9.66 | 4 |
| Sep ’24 | €8.00 | €8.95 +11.9% | 4.1% | €9.50 | €8.50 | €9.92 | 4 |
| Aug ’24 | €8.70 | €9.25 +6.3% | 6.0% | €10.00 | €8.50 | €9.88 | 4 |
| Jul ’24 | €9.39 | €9.25 -1.5% | 6.0% | €10.00 | €8.50 | €9.38 | 4 |
| Jun ’24 | €9.42 | €9.25 -1.8% | 6.0% | €10.00 | €8.50 | €9.30 | 4 |
| May ’24 | €9.15 | €8.93 -2.5% | 11.8% | €10.00 | €7.20 | €8.28 | 4 |
| Apr ’24 | €7.47 | €8.43 +12.8% | 10.6% | €9.50 | €7.20 | €7.61 | 4 |
| Mar ’24 | €8.02 | €9.03 +12.5% | 7.0% | €9.60 | €8.00 | €8.00 | 4 |
| Feb ’24 | €8.90 | €9.90 +11.2% | 7.4% | €11.00 | €9.00 | €7.17 | 4 |
| Jan ’24 | €8.52 | €9.90 +16.2% | 7.4% | €11.00 | €9.00 | €7.06 | 4 |
| Dec ’23 | €8.65 | €9.90 +14.5% | 7.4% | €11.00 | €9.00 | €7.06 | 4 |
| Nov ’23 | €9.27 | €11.78 +27.0% | 6.7% | €12.50 | €10.60 | €7.39 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Nexstim
€34.4m
A medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
NXTMH
€5.08
7D
-0.8%
1Y
106.5%
Revenio Group Oyj
€718.1m
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.
REG1V
€27.00
7D
-5.3%
1Y
9.8%
Optomed Oyj
€77.5m
Manufactures and sells handheld fundus cameras in Finland and internationally.
OPTOMED
€3.96
7D
-3.9%
1Y
29.7%